Lung cancer accounts for 8.1% of cancer-related deaths in India. Data from the National Cancer Registry Programme (NCRP) and GLOBOCAN project approximately 111,328 new cases will be diagnosed in 2025. Late diagnosis (75% of cases in stages 3–4) and limited access to specialized treatment contribute to a low five-year survival rate of about 15%, compared to 45% in developed countries.

“India market approval is a major step forward in our global mission to transform lung cancer care,” said Matt Baker, CEO at Body Vision Medical. “We are thrilled to partner with Assiz & Sarah Healthcare to make LungVision available in India, where there is a definitive need for earlier diagnosis of suspicious pulmonary nodules.”

LungVision, an AI-powered advanced imaging system that transforms any C-arm into a 3D imaging system, empowers physicians with real-time navigation and enhanced visualization to achieve more precise and accurate bronchoscopic biopsies. By enabling more confident diagnoses, LungVision supports the clinical goals of the NLCSP and has the potential to improve patient outcomes.